Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0AA6Z
|
|||
| Former ID |
DCL000950
|
|||
| Drug Name |
Rambazole
|
|||
| Synonyms |
Talarozole; 201410-53-9; R-115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)benzo[d]thiazol-2-amine; R115866; CHEMBL459505; C21H23N5S; Rambazole (TN); Talarozole (USAN/INN); Talarozole [USAN:INN]; R 115866; N-(4-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)phenyl)-2-benzothiazolamine; Talarozole pound> SCHEMBL721201; CHEBI:102167; MolPort-018-666-712; SNFYYXUGUBUECJ-UHFFFAOYSA-N; BCP28256; BCP21218; BDBM50253810; 0328AB; AKOS005067289; DB13083; CS-1343; NCGC00378894-01; HY-14531; AX8224298; D09385; W-5674; MEN13510
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Phase 2 | [1] | |
| Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Investigative | [2] | ||
| Company |
Barrier
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H23N5S
|
|||
| Canonical SMILES |
CCC(CC)C(C1=CC=C(C=C1)NC2=NC3=CC=CC=C3S2)N4C=NC=N4
|
|||
| InChI |
1S/C21H23N5S/c1-3-15(4-2)20(26-14-22-13-23-26)16-9-11-17(12-10-16)24-21-25-18-7-5-6-8-19(18)27-21/h5-15,20H,3-4H2,1-2H3,(H,24,25)
|
|||
| InChIKey |
SNFYYXUGUBUECJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 201410-53-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:102167
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cytochrome P450 26 (CYP26A1) | Target Info | Inhibitor | [1] |
| Substance-K receptor (TACR2) | Target Info | Antagonist | [2] | |
| KEGG Pathway | Retinol metabolism | |||
| Metabolic pathways | ||||
| Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Pathwhiz Pathway | Retinol Metabolism | |||
| Reactome | G alpha (q) signalling events | |||
| WikiPathways | Vitamin A and Carotenoid Metabolism | |||
| Metapathway biotransformation | ||||
| Oxidation by Cytochrome P450 | ||||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Adipogenesis | ||||
| Phase 1 - Functionalization of compounds | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. | |||
| REF 2 | Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor. Eur J Pharmacol. 2005 Jun 1;516(2):104-11. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.